Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Histamine and Tubocurarine

supplement:

Tubocurarine

Research Papers that Mention the Interaction

Mivacurium, atracurium and tubocurarine caused 370%, 234% and 252% increases in plasma histamine concentrations at 1 min, respectively.
British journal of anaesthesia  •  1995  |  View Paper
Tubocurarine caused 240% and 210% increases in plasma concentration of histamine at 1 and 3 min, respectively.
British journal of anaesthesia  •  1991  |  View Paper
It is possible that the patient was sensitive to histamine released by d-tubocurarine as she had a minor past history of bronchial asthma.
The Australian and New Zealand journal of surgery  •  1966  |  View Paper
…,histamine enhanced the amplitude of the depolarizing … blocking the afterhyperpolarizing potential with d-tubocurarine or apamin, and in the presence of tetrodotoxin and d-tubocurarine or apamin, indicating a postsynaptic action of … on the depolarizing afterpotential that is not simply a reflection of a decrease in the afterhyperpolarizing potential.
Neuroscience  •  1993  |  View Paper
The vertebrate HA receptor antagonist, cimetidine, and the nicotinic receptor antagonist, d-tubocurarine , but not other known vertebrate HA receptor antagonists, reversibly blocked the action of HA.
The Journal of experimental biology  •  1989  |  View Paper
injections of tubocurarine (greater than 5 mg kg-1; corresponds to tubocurarine 4 X 10(-4) mol litre-1 in the plasma of the rats) evoked a phasic increase in plasma histamine concentration.
British journal of anaesthesia  •  1986  |  View Paper
Abstract Compound 48/80 and tubocurarine , which are known to release mast cell histamine in vitro , increased the outflow of histamine from blood-perfused canine subcutaneous adipose tissue in situ .
Second and subsequent injections of either compound 48/80 or tubocurarine were much less effective in releasing histamine and lipolytic products, indicating tachyphylaxis; cross tachyphylaxis between compound 48/80 and tubocurarine also occurred.
European journal of pharmacology  •  1971  |  View Paper
A larger dose of d-tubocurarine (1 mg/kg) produced a profound fall in MAP (average decrease 78 mm Hg), followed by signs of histamine-induced catecholamine release (transient rebound increases in MAP, PP, and HR) and more than a four-fold increase in circulating histamine.
The muscle-paralyzing dose of d-tubocurarine (0.4 mg/kg) produced an average decrease in MAP of 44 mm Hg together with a marked decrease in SPGSA to 7.8 per cent of the control value and a twofold increase in blood histamine concentration.
Anesthesiology  •  1970  |  View Paper